Summary Forty fixed tissue sections from patients with small cell lung carcinoma (SCCL) have been stained with a panel of 10 monoclonal antibodies using a peroxidase anti-peroxidase method and the incidence of staining has been compared to patient characteristics at presentation and to survival. An inverse association between HMFG2 staining and survival was found with median survival in HMFG2 negative patients 13 months compared to 8 months for HMFG2 positive patients. No such association was found with the other antibodies and no association was found between staining and disease extent or primary versus secondary deposits with this panel of antibodies. Epidermal growth factor receptor was detected in 3/38 presentation biopsies and in these 3 patients mean survival was only 5 months. Further prospective study of HMFG2 as a prognostic indicator in SCCL is suggested.
Small cell carcinoma of the lung (SCCL) remains a highly lethal disease, despite the advent of modern chemotherapy, with overall long-term disease-free survival expected in only (10%) (Aisner et al., 1983) . For patients who have little chance of long-term survival the goal of therapy is palliation of symptoms, whilst for the minority who have a better prognosis, intensive therapy may be indicated in order to achieve long-term control.
Using current clinical and biochemical evaluation it is possible to obtain only a crude determinant of prognosis. Recently studies of cell lines derived from human SCCL have provided data giving insights into the biochemical, morphological and genetic diversity of this cancer. One result of these studies has been the development of monoclonal antibodies to examine cell surface antigens associated with SCCL. In terms of prognostic value the minimum benefit would be to improve the current unsatisfactory techniques which give information about the extent of disease. Potentially the linking of clinical events to cellular behaviour could give an insight to the ways in which in vitro technology should be further developed to improve the clinical outcome of this highly malignant cancer. In this initial study we have examined the cell surface antigen expression in a series of 40 tissue sections from patients with SCCL in whom clinical information was available. The aim was to identify antigen expression which might be related to response to treatment or prognosis. 
Immunohistochemistry
The 5,pm sections were dewaxed and rehydrated.
Endogenous peroxidase activity was blocked with freshly prepared 0.3% hydrogen peroxide in methanol for 30 min and the slides then washed in tris buffered saline (pH7.4). Antigen recognition was enhanced by trypsinisation (0.1% Sigma crude trypsin in 0.01% EDTA) prior to incubation with MoAbs. Thereafter a standard 3 step PAP (peroxidase anti-peroxidase) technique was applied (Sternberger, 1979) and background staining was reduced by the use of sheep serum (1:5 dilution). The peroxidase end product was developed using diaminobenzidine tetrahydrochloride/H202 followed by haematoxylin counter staining. Assessment Sections were scored as positive if 10% or more of the cells stained. Two observers assessed the slides independently. A Mann-Whitney test was applied to the survival data in the HMFG2 groups.
Patients
The study groups comprised patients with histologically confirmed SCLC in whom the extent of disease, treatment details and response to therapy and survival were known.
All patients received combination chemotherapy as primary therapy except one patient who had a surgical resection of a T2 N2 Mo lesion. The chemotherapy consisted of a combination of (a) methotrexate (200 mg m 2) by 24 h infusion with folinic acid rescue, cyclophosphamide (1 gm-2) and CCNU (100mg-2) in 2 patients; (b) methotrexate (200mgm-2) by 24h infusion with folinic acid rescue, cyclophosphamide (1 gm-2) and etoposide (120 mgm-2 days 1-3) in 15 patients; (c) vindesine (3 mg m 2) and etoposide (120mgm-2, days 1-3) in 13 patients. In addition one patient in group (b) received high dose melphalan 140 mgm-2 with autologous marrow rescue as late intensification therapy and 3 patients in group (b) received radical radiotherapy (45Gy in 20 fractions over 4 weeks) to the primary site and mediastinum, including the patients receiving melphalan. Regimens (a) and (b) were considered as intensive chemotherapy for SCCL .
Results
The staining patterns of the 31 primary bronchial biopsies in 31 patients were HMFG1 positive 10/15 tested, HMFG2 17/31, B5 27/29 (2 samples lost in processing), 534F8, 15/31 and F4, 2/31. In addition Mo2 showed positive staining in 5/18 samples tested, Leu-7 in only 3/28 and neither a bombesin (0/18) nor mycl-6E10 (0/22) stained positively. Table III. Of the patients who stained positively for HMFG2 none is alive, and of those who stained negatively 4 are still alive at 7, 14, 22 and 56 months. As regards intensity of therapy between these groups they are very evenly balanced with 9/17 HMFG2+ve and 8/13 HMFG2-ve receiving intensive chemotherapy. Biopsies were available from 7 metastatic sites -2 liver, 3 lymph node and 2 skin nodules. A heterogenous staining pattern similar to the primary tumours was observed with the panel of antibodies in these metastases, although one lymph node and one skin nodule showed moderately strong staining with F4. The patient with the lymph node had originally been negative for F4 in bronchus and skin nodule before chemotherapy but developed further disease 10 months later and died at 14 months. The patient with the skin nodule died of extensive disease at 1 month following commencement of chemotherapy. The two patients who demonstrated F4 staining in their primary lung biopsies died at 6 and 8 months respectively. One patient who had bronchial biopsies performed before and after intensive chemotherapy (regimen b), including radical radiotherapy, showed microscopic residual disease. The initial tumour stained positively with B5 and 534F8 whereas the residual tumour post chemotherapy stained additionally with CAM 5.2 and HMFG2.
Discussion
Despite modern intensive chemotherapeutic and radiotherapeutic intervention, long-term survival in SCCL is limited to 10% of those developing the disease. Although these survivors will usually have limited disease at presentation this by no means guarantees long-term survival and although some helpful prognostic factors have been identified (Souhami et al., 1985) further useful prognostic markers would be welcome. The identification of a poorer prognosis associated with the expression of the epithelial antigen identified by HMFG2 is thus of interest. Although the numbers in this retrospective study are small, and we cannot rule out a chance statistical finding, the result is significant and four of the HMFG2 negative patients are still alive as compared with none who were HMFG2 positive. Treatment given to these groups is very evenly balanced with no obvious bias towards more intensive therapy. Thus of those positive for HMFG2, 53% had intensive treatment compared with 57% of those who were negative. When the two groups are analysed for clinical disease extent, one of the major prognostic factors in SCCL, then of those positive for HMFG2 88% had limited disease as opposed to only 64% of those who were negative. Therefore despite somewhat more extensive disease present amongst the HMFG2 negative group the lack of HMFG2 staining predicted a better prognosis. The significance of HMFG2 positivity following treatment in the patient who had previously been HMFG2 negative is uncertain but may have represented the emergence of a new cell clone.
The epithelial glycoprotein identified by HMFG2 (Burchell et al., 1983 ) is well preserved in formalin but some measure of denaturing cannot be excluded. In fresh tumour biopsy samples of SCCL using this MoAb we have a positivity rate approaching 93% although this includes faint and patchy staining. Thus formalin fixation may quantitatively denature the HMFG2 antigen and we feel that a prospective study of this antibody (on unfixed tissue) with regard to clinical outcome is indicated. In particular there is the potential now for the prospective study of HMFG2 in serum in SCCL in relation to clinical outcome and disease detection. HMFG2 will detect other carcinomas such as breast (Burchell et al., 1984) and labelling of HMFG2 with 12 31 has been used to localise ovarian tumours effectively (Epenetos et al., 1982) . The absence of HMFG1 staining in breast carcinoma has been shown to predict poor survival (Wilkinson et al., 1984) , but another study (Berry et al., 1985) could not demonstrate prognostic significance of HMFG1 or HMFG2 staining in the same cancer. With regard to the differential diagnosis of SCCL an effective panel of antibodies may be emerging (Hay et al., 1986) . Distinction from lymphoma is now possible but further studies on staining patterns of non-small cell lung cancer are required. The cytokeratin antibody anti CAM 5.2 identifies a low molecular weight cytokeratin restricted to simple epithelia and was positive in 50% of our cases but without prognostic significance. This, together with the HMFGI and HMFG2 antigens, supports the notion of an epithelial origin for SCCL. Smaller numbers were studied using HMFG1 compared with HMFG2 as the latter has been found to be more strongly expressed on tumour glycoproteins (Burchell et al., 1983) . However HMFG1 showed a similar staining pattern to HMFG2.
The neuroendocrine MoAb 534F8 showed moderately strong staining in 48% of biopsies but without obvious prognostic significance. The anti-bombesin MoAb did not appear to react with fixed tissue in this study although in fresh tissues 13/17 stained positively. The lymphoidassociated MoAbs were of interest with the monocyte marker Mo2 positive in 28% of samples and the B-cellrestricted activation antigen, B5, (Freedman et al., 1985) very strongly expressed in 93% of samples. The NK cell/neuroendocrine MoAb anti-Leu 7 was positive in only 11% of these fixed tissues compared with 86% when used in fresh SCCL (unpublished data). Expression of p62c-myc was not seen in 22 tested samples. F4, the internal portion of the epidermal growth factor (EGF) receptor (Gullick et al., 1986) , was expressed infrequently in the primary biopsies 2/31 but perhaps significantly was expressed in 2/7 metastatic sites. In the case of one of the latter F4 was not expressed in the primary site or in a skin nodule prior to chemotherapy. At relapse 10 months later the metastatic lymph node expressed F4 and this patient died 4 months later. The mean survival of the 3 patients in whom F4 was expressed at diagnosis was 5 months. In none of these sections was staining strong or homogeneous. Cerny et al. (1986) (Sainsbury et al., 1985) , and EGF receptors were more likely to be present in invasive transitional cell carcinoma of bladder than in superficial bladder tumours (Neal et al., 1985) . These findings would suggest that some epithelial tumours positive for EGF receptors are likely to have a poor prognosis and further studies with SCCL may confirm that for this disease.
In conclusion, an increasing panel of MoAbs is available for characterising SCCL. Some of these will be of value in differential diagnosis. This study indicates that the presence of HMFG2 on human SCCL may represent a poor prognostic sign and requires prospective evaluation. In addition expression of the EGF receptor may indicate a particularly unfavourable prognosis.
